Results 51 to 60 of about 91,755 (270)

18F‐FGln PET/CT Imaging of Glutamine Uptake Has Potential for Predicting Immunotherapy Response in Hepatocellular Carcinoma

open access: yesAdvanced Science, EarlyView.
18F‐FGln PET/CT imaging serves as a marker of Gln uptake in hepatocellular carcinoma. Tumors with high Gln uptake drive Treg‐mediated immunosuppression and immune evasion during antitumor immunotherapy. Conversely, tumors with low Gln uptake maintain sufficient Gln in the TME, suppressing Tregs and enabling cytotoxic T cells to inhibit tumor growth ...
Yi Liu   +8 more
wiley   +1 more source

Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure

open access: yesFrontiers in Oncology, 2021
BackgroundNivolumab and regorafenib are approved second-line therapies for patients with hepatocellular carcinoma (HCC) after sorafenib failure.
Yuan-Hung Kuo   +8 more
doaj   +1 more source

Can Chemoradiotherapy Expand Immune Checkpoint Blockade Responsiveness in Mismatch Repair‐Proficient Rectal Cancer?

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
ABSTRACT Immune checkpoint blockade (ICB) has transformed the treatment of mismatch repair‐deficient (dMMR) colorectal cancer but produces no meaningful benefit in advanced mismatch repair‐proficient (pMMR) disease. In the neoadjuvant setting, however, pathological responses have been reported in a subset of pMMR tumors, suggesting that clinical ...
Kimihiro Yamashita   +4 more
wiley   +1 more source

Nivolumab induced morphea

open access: yes, 2020
Nivolumab induced ...
Dal Bello G   +3 more
core   +1 more source

Nivolumab induced myxedema crisis

open access: yesJournal for ImmunoTherapy of Cancer, 2017
Background Nivolumab is an anti-programmed cell death (anti-PD-1) monoclonal antibody that is approved by Food and Drug Administration for treatment of metastatic non-small cell lung cancer, metastatic melanoma, relapsed Hodgkin lymphoma and advanced ...
Uqba Khan   +4 more
doaj   +1 more source

Analyses of Nivolumab Exposure and Clinical Safety Between 3-mg/kg Dosing and 240-mg Flat Dosing in Asian Patients with Advanced Renal Cell Carcinoma in the Real-World Clinical Setting

open access: yesTranslational Oncology, 2020
We aimed to identify the clinical characteristics related to increased nivolumab exposure in Japanese patients with renal cell carcinoma (RCC) in real-world clinical setting.
Renpei Kato   +11 more
doaj   +1 more source

Real-world treatment sequencing and survival in previously treated advanced renal cell carcinoma patients receiving nivolumab monotherapy: a UK retrospective cohort study

open access: yesBMC Cancer, 2022
Background The CheckMate 025 trial established nivolumab monotherapy as one of the standards of care in previously treated advanced or metastatic renal cell carcinoma (aRCC). However, supporting real-world data is lacking.
T. Waddell   +11 more
doaj   +1 more source

Nivolumab – Pearls of evidence

open access: yesIndian Journal of Medical and Paediatric Oncology, 2017
Nivolumab is one of the most extensively studied immune checkpoint inhibitors across various tumor types. In this narrative review, the current clinical efficacy and safety data of anti-programmed death-1 (PD-1) nivolumab for nonsmall cell lung cancer (NSCLC) and renal cell cancer (RCC) are elucidated.Systematic search was done on Pubmed, Medline ...
openaire   +2 more sources

Growth Differentiation Factor 15 as a Cerebrospinal Fluid Biomarker for the Diagnosis and Prognosis of Leptomeningeal Metastasis

open access: yesAnnals of Neurology, EarlyView.
Objective As leptomeningeal metastasis (LM) has a poor prognosis, reliable cerebrospinal fluid (CSF) diagnostic biomarkers are urgently needed. This study evaluated the diagnostic value of CSF growth differentiation factor 15 (GDF15) in LM from lung adenocarcinoma (LUAD) and breast cancer (BC).
Haoyu Ruan   +12 more
wiley   +1 more source

Enhancing Effector Jurkat Cell Activity and Increasing Cytotoxicity against A549 Cells Using Nivolumab as an Anti-PD-1 Agent Loaded on Gelatin Nanoparticles

open access: yesGels
The current research investigated the use of gelatin nanoparticles (GNPs) for enhancing the cytotoxic effects of nivolumab, an immune checkpoint inhibitor.
Dalia S. Ali   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy